The storage conditions for peptides depend on the specific material, its formulation, type of packaging, physical state, safety system, and intended use. There is no single storage temperature, freezing rule, or shelf life period that can be reliably applied to each peptide powder, solution, cosmetic, pharmaceutical product, analytical sample, or biological sample.
Information regarding storage is only of scientific importance when it is known what material was actually being studied, under what conditions it was stored, for how long the observation lasted, and which properties remained at an acceptable level during that time.
Low temperature can slow down some chemical reactions. This is one of the reasons why temperature takes such an important place in discussions regarding the stability of peptides. However, it is not the only factor. Humidity, oxygen, light, formulation components, concentration, the chemical environment of the solution, contact with the container surface, and the way the material is handled can all influence what happens to the peptide over time.
Freezing also requires special attention. A frozen solution is not simply the same solution at a lower temperature. The formation of ice changes the physical environment surrounding the dissolved molecules and can affect local concentrations, interfacial areas, and molecular interactions. Therefore, freezing should not be automatically considered the most protective method of storage for any peptide preparation.
Studies show how problems can be related to this. Chemical reactions were also observed in dried peptide formulations; surface adsorption can reduce the recovery of the peptide from diluted solutions, and biological samples containing peptide or protein analytes can react differently to repeated cycles of freezing and thawing.
The overall conclusion is simple: storage conditions should be evaluated for a specific material, and not reduced to a universal rule such as „all peptides should be stored in the freezer”.
Why do the storage conditions depend on the type of material?
The name of the peptide itself does not describe the entire preparation.
The amino acid sequence is fundamental to the identity of a peptide, but the sequence alone does not describe all the factors that can influence its stability.
Products containing the same peptide may differ in chain ends modifications, anti-ions, concentration, water residue content, formulation components, solution chemical environment, physical state, and packaging type.
This means that the same peptide name can refer to several very different storage-related issues.
The dry research material containing a specific peptide does not have to be equivalent to a water-based analytical standard containing the same sequence. Neither of these materials must also correspond to the finished pharmaceutical product in which the same molecule is present together with carefully selected excipients and within a validated packaging system.
The result regarding storage obtained for one preparation cannot therefore be automatically transferred to another simply because both contain a peptide with the same name.
Even the term „powder” conveys relatively little information.
The powder may contain a peptide along with salts, excipients, anti-ions, water residues, and other formulation components. Two materials that look like a similar white powder can therefore create completely different chemical and physical environments.
Based on the appearance alone, it is not possible to determine the water content, the composition of the formulation, the presence of degradation products, or what storage conditions have actually been validated.
Stability means maintaining certain properties
A peptide is not simply „stable” or „unstable” in every possible sense of the word.
Stability always refers to a specific property or set of properties that are evaluated over time.
One study may determine what portion of the chemically unchanged target peptide remains in the sample and whether degradation products appear. Another may analyze aggregation or elution. Still others may assess biological activity, analytical recovery, or other functional property.
These parameters do not have to change at the same rate.
Chemical integrity refers to whether the intended molecular structure remains intact and whether chemical degradation products accumulate. Confirmation of chemical integrity does not automatically mean the preservation of all functional properties.
Physical stability may include aggregation, precipitation, particle formation, or other changes in physical state. A preparation may remain chemically recognizable while exhibiting undesirable physical changes.
Functional activity answers the question of whether the material still retains a specific effect in a specific test. However, the preservation of activity does not in itself prove that each molecule has remained chemically unchanged or that no impurities have formed.
Analytical recovery determines the amount of material that can actually be recovered and measured. Its reduction can result from chemical degradation, but also from adsorption on surfaces, precipitation, or limitations of the analytical method used.
Microbiological quality is another issue. A preparation can remain chemically stable but not meet the appropriate microbiological requirements. Conversely, a correct microbiological test result does not confirm chemical stability.
The appropriate stability parameters therefore depend on the intended use of the material.
The analytical standard requires reliable measurement properties. A laboratory reagent may require specific chemical and analytical properties. A finished medicinal product, on the other hand, has its own specifications, packaging, labeling, and stability requirements.
Therefore, the statement „the peptide remains stable” is incomplete from a scientific point of view if it is not known what exactly „stable” means in a given context.
Model studies explain the mechanisms, but do not set universal durability terms.
Laboratory degradation studies are valuable because they help to understand how a molecule can undergo changes.
Scientists can deliberately expose peptides to chemical or physical stress and then characterize the resulting products. Such experiments help identify degradation pathways and develop analytical methods capable of detecting significant changes.
However, such studies should not be equated with durability testing.
Forced degradation involves deliberately subjecting a molecule to conditions chosen to accelerate or reveal possible degradation processes.
The stability or shelf life study, on the other hand, answers another question: whether the actual preparation remains within the limits specified in the specifications for the determined time under conditions corresponding to its intended storage.
The forced degradation experiment can therefore show the susceptibility of the peptide to oxidation, light, hydrolysis, or other processes, but it does not automatically determine how quickly this process will occur during normal storage.
Similarly, detecting a specific degradation mechanism in one formulation does not establish a universal storage term for all preparations containing the same peptide.
Both types of research complement each other, but their conclusions are not interchangeable.
Peptides in powder and peptides in solution
Drying changes the environment, but it does not stop all the chemistry
Removing a significant portion of the water from the formulation can improve stability in certain situations.
Lower water content can slow down some reactions occurring in the solution and change the mobility of molecules. This is one of the reasons for the widespread use of drying and lyophilization in pharmaceutical and laboratory applications.
Drying does not, however, stop all chemical processes.
The lyophilized product does not have to be completely water-free as well. After the drying process, residual moisture may remain, which affects both the chemical reactions and the physical properties of the dried material.
Studies of model peptides in amorphous lyophilized systems have shown that even in dried formulations chemical reactions can occur, such as deamidation or the formation of covalent products.
Therefore, it is necessary to distinguish between reduced water content and proven stability.
A smaller amount of water may contribute to increased stability, but the dry appearance of the preparation itself does not constitute proof of its stability.
The white powder may look the same, although at the molecular level changes that are invisible to the naked eye occur.
The ingredients of the formulation can affect the dried material
Peptides are often stored together with other components, rather than as completely isolated molecules.
In formulated products, additional substances, often referred to as excipients, can perform functions related to the production process, physical stabilization, volume enhancement, or other properties of the formulation.
Their action depends on the entire chemical system.
An ingredient that works in one formulation cannot be automatically considered universally protective for every peptide product.
Studies of dried peptide formulations have shown that impurities associated with the formulation components can participate in degradation processes in certain situations.
This does not mean that the ingredient itself is always unsuitable.
It does, however, show that stability applies to the entire formulation, and not just to the isolated peptide molecule.
Changes in the excipient, its quality or concentration, the production process or the amount of residual water may limit the ability to directly apply previous stability data.
Solutions introduce additional variables
When the peptide is in a solution, other factors take on importance.
The composition of the solvent, pH, ionic environment, peptide concentration, and the presence of other components can affect chemical and physical behavior.
A decrease in the amount of peptide detected in the solution can have several causes.
The peptide could have undergone chemical degradation.
It could have been aggregated or displaced.
It could have bonded to the surface of the container.
The slight loss may also be partly due to the way the sample is handled or to limitations of the analytical system.
These are different phenomena that require different types of evidence.
If less peptide can be recovered from the solution, this does not automatically mean that its peptide bonds have been chemically destroyed.
On the other hand, a completely transparent solution does not confirm that all the molecules remained chemically unchanged.
Some degradation products remain completely soluble and visually indistinguishable from the starting material.
Therefore, visual assessment and analytical characterization answer different questions.
Different drying methods require separate evaluation
The term „dried” can refer to various technological processes.
Freeze-drying and spray drying, for example, lead to the production of a dry material using various physical processes.
Their influence on the structure of the peptide, residual moisture, particle properties, and subsequent stability should be evaluated experimentally, rather than being inferred solely on the basis that both processes lead to the formation of a powder.
In studies on the development of processes for peptide preparations, among other things, residual moisture, the behavior of the material in a solid state, particle properties, aggregation, and chemical degradation after drying are analyzed.
If a given drying method allows the material to be obtained without significant degradation, this means that the process can operate under the tested conditions.
However, this does not establish an unlimited shelf life.
Effective drying of the material and validated long-term storage are two separate scientific claims.
Temperature and exposure to humidity
Lower temperature is not a complete storage specification
Temperature can affect the speed of chemical reactions.
In many systems, lowering its temperature slows down certain degradation processes. This general principle helps explain why some biological and pharmaceutical materials are stored in refrigerated or frozen conditions.
However, the temperature value alone does not constitute a complete storage specification.
The type of material, formulation, storage time, packaging, and allowable range of changes are also important.
For example, stating that the material was stored in a refrigerator conveys less information than might be thought.
The setting of the cooling device does not necessarily correspond to the entire temperature history that the material actually experienced. The temperature may vary in different parts of the device, change during opening of the door, transport, or temporary deviations from the established conditions.
From a scientific point of view, therefore, it is important to consider the conditions under which the material actually experienced the process and whether these conditions remained consistent with the stability data for the particular preparation.
For this reason, in pharmaceutical stability studies, storage conditions are conclusions derived from studies conducted over time, rather than a single temperature assigned to everything that is described as a peptide.
Moisture can change both the rate and the course of degradation
Water can affect the stability of peptides in several ways.
In solution, it forms the basic chemical environment surrounding the molecule.
In dried material, even a small amount of residual water can affect the mobility of molecules, the physical properties, and the course of chemical reactions.
Importantly, the relationship between humidity and degradation is not always straightforward.
More water can accelerate some processes, but individual degradation pathways may react differently to changes in the physical environment.
Studies of amorphous materials containing peptides have shown that changes in water content can modify the course of degradation and that not all degradation products react to this change in the same way.
Therefore, the simple principle „the more dry the material, the greater the stability” is not scientifically justified for every formulation.
Residual moisture should be treated as a measurable formulation parameter.
The proper question is about what range of moisture is compatible with the quality requirements of a particular material.
The ambient humidity and the water present in the preparation are not the same thing
Ambient humidity and residual humidity are related concepts, but they mean different things.
Ambient humidity describes the amount of moisture in the air surrounding the package.
Residual moisture means water already present in the material or formulation.
The influence of external humidity on the preparation depends, among other things, on the packaging system, the tightness of the closure, and the handling history of the material.
A tightly sealed container can create a completely different environment than a container that is repeatedly opened and exposed to the surrounding air.
Therefore, repeated opening can change the history of the exposure of the preparation.
It should not be assumed automatically that two containers located in the same refrigerator were stored under equivalent conditions if one remained closed and the other was repeatedly opened.
Therefore, the storage requirements should be related to the packaging under investigation and the way the material is handled, and not only to the room or device in which it was located.
Transferring the product to another container may also limit the usefulness of the original stability data, as the new container may differ in terms of moisture permeability, surface properties, light protection, or closure quality.
Light and oxidation are additional factors
Temperature and humidity are not the only environmental factors that can affect peptide preparations.
Some amino acid sequences and formulations may be susceptible to oxidation-related changes or exposure to light.
The significance of these processes depends on the specific molecule and the formulation.
In stress studies, peptides can be deliberately exposed to oxidizing agents or light to identify possible degradation products and assess the ability of analytical methods to detect them.
Such experiments are valuable for determining the susceptibility of a molecule.
However, the results of a targeted photostability or oxidative stress study cannot be directly translated into a universal statement determining how long an unknown peptide preparation can remain in ordinary room lighting.
A reliable description of stability should therefore distinguish the conditions deliberately applied to cause degradation for analysis purposes from those proposed for routine storage.
The history of freezing and thawing and the impact of packaging
Freezing is a physical transformation
Freezing should not be understood solely as a further reduction in the temperature of the liquid.
When water freezes, ice forms, and the remaining non-frozen areas may differ chemically from the original solution.
The dissolved substances can concentrate in the remaining liquid phase, new interfacial surfaces can form, and the local environment surrounding the molecules can change.
In the case of some molecules, these changes can affect the structure, intermolecular interactions, or analytical recovery.
Protein studies revealed structural abnormalities and aggregation associated with freezing and repeated cycles of freezing and thawing.
Protein is not the same as a short peptide, therefore the results of such studies cannot be used to determine a universal cycle limit for all peptides.
However, these studies show why freezing should be analyzed separately, rather than simply being treated as very intensive cooling.
The general rule therefore is: freezing changes the physical environment of the preparation, and the significance of this change must be evaluated for the specific material.
There is no universally acceptable number of freezing and thawing cycles
Statements such as „one cycle of freezing and thawing destroys the peptides” or „the peptides withstand five cycles” are too general to be considered scientifically reliable.
The effects of repeated freezing and thawing depend on the type of material, its formulation, and the property that researchers measure.
Biologic samples are particularly good at showing this.
When several different endocrine analytes are analyzed after repeated cycles of freezing and thawing, some may remain relatively unchanged, while in others measurable differences are observed.
This means that even substances found in the same sample matrix can react differently.
However, the study of biological samples should not be considered as confirmation of the structural integrity of purified peptide preparations.
Blood, serum and plasma contain proteins, salts, lipids and many other substances. The purified peptide solution forms a completely different physical and chemical system.
The available data therefore do not justify any of the extreme assumptions.
It should not be assumed that every cycle of freezing and thawing must destroy every peptide.
It should also not be assumed that multiple cycles are never relevant.
The validated limit applies to a specific material, its formulation, and the analytical parameter being evaluated.
Adsorption is not the same as degradation
One of the most important distinctions in the storage and analysis of peptides is the difference between adsorption and chemical degradation.
Adsorption occurs when molecules bond to the surface.
The peptide can therefore leave the main volume of the solution and bind to the container wall or another surface without the need for its chemical destruction.
If the analysis only covers the liquid phase, the measured concentration may be reduced.
At that time, the impression may arise that part of the peptide has been „lost”.
The lower analytical recovery alone does not explain the mechanism of this phenomenon.
The molecule could undergo chemical degradation, dislocation, aggregation, or adsorption on the surface.
Analytical studies of peptides have shown that the surfaces of containers, sample vials, and even components of chromatographic systems can affect the recovery and transfer of residues between analyses.
Therefore, the apparent loss of material during storage may require an assessment of both the peptide itself and the measuring system.
Chemical degradation, surface-related loss, and analytical transfer are separate issues, although each of them can affect the final measurement result.
Glass and plastic cannot be grouped into a single universal category.
Often one can encounter simplified recommendations according to which peptides should always be stored in glass or always in a specific type of plastic.
The available data do not justify such a universal ranking.
The terms „glass” and „plastic” encompass a wide range of materials.
The chemical properties of the surface, the processing method during production, the geometry of the container, and other characteristics can all influence the effects of molecules on the surface.
The peptide sequence, its concentration, and the composition of the surrounding formulation are also important.
Analytical studies comparing the recovery of peptides from different laboratory materials have shown that specialized materials with limited binding affinity do not necessarily provide the greatest benefit in every situation studied.
This does not mean that specialized containers are of no value.
It simply means that their usefulness depends on the specific material and application.
An appropriate container is one whose properties have been demonstrated for the intended use, and not one that has been chosen solely because the material name or marketing description suggests better protection.
„Peptide refrigerator” or a transport case is equipment, not proof of stability
A separate refrigerator, mini-refrigerator, insulated transport case or organizer can help maintain or control the storage environment.
However, the equipment itself does not determine the conditions that a specific peptide preparation requires.
The device sold as a „peptides refrigerator” does not automatically ensure uniform temperature distribution, does not preclude accidental freezing of the material, and does not prove that the device complies with the specific formulation.
These are separate issues.
The evaluation of the equipment’s performance concerns whether the device reliably produces and maintains the required environment.
The assessment of the stability of a peptide concerns whether a specific preparation remains within the limits of the appropriate specifications in such an environment.
Both issues are related, but they are not the same thing.
Similarly, an isolated transport container cannot in itself determine how long an unknown peptide preparation retains the required properties during transport.
Such a claim would require a joint assessment of the specific material, packaging, environmental conditions, and the time of transport.
Storage information and stability documentation
A credible claim regarding stability sets its limits
A statement such as „stable at low temperature” contains too little information to determine scientifically justified storage conditions.
Credible information about stability indicates which preparation it concerns, what its formulation and packaging are, under what conditions it was tested, how long the observation period lasted, what analytical tests were performed, and according to which criteria was assessed whether the material remained acceptable.
The documentation may include, among other things, information about the batch, the date of production or preparation, the history of storage, the sampling schedule, the analytical methods, and the results obtained over time.
This does not mean that every product label must contain a full description of the entire research program.
The most important thing is to distinguish between a storage instruction supported by appropriate evidence and an unjustified generalization resulting solely from the fact that the material in question is a peptide.
Methods indicating stability must detect significant changes
The analytical method indicating stability should enable the detection of changes that are significant for the deterioration of the quality of the preparation.
Just obtaining a signal corresponding to the peptide does not necessarily confirm full stability.
For example, a biological or immunological test can still recognize a specific fragment of the molecule, even though another area of it has been modified.
Similarly, the analytical method can measure the total amount of material, without properly distinguishing between the specific degradation product.
Different quality characteristics may therefore require the use of different methods.
Chromatographic methods can help in separating degradation products, mass spectrometry in characterizing molecular changes, and other techniques may be needed to evaluate physical or functional properties.
The most important principle is that the analytical method must be appropriate for the specific question of stability.
The shelf life of a closed product and the stability after opening are different matters.
The closed container and the container repeatedly opened have different exhibition histories.
Opening can cause the material to come into contact with the surrounding environment.
Repeated use of the contents may lead to additional changes related to temperature, humidity, or other handling conditions of the product.
Dissolving or diluting can alter the preparation even further, transforming the dry material into a solution with a different chemical and physical environment.
Therefore, the shelf life of an unopened product and the stability after it has been used are separate concepts.
The shelf life indicated for the closed preparation should not be automatically extended to the same material after opening, dilution, dissolution, or transfer to another container.
The general rule is that the stability period established for a single state of the preparation applies to that state only, unless the available data allow the extension of the claim to other conditions.
The date of the re-examination and the expiration date do not mean the same thing
The date of the re-examination and the expiration date are not interchangeable concepts.
In pharmaceutical production, the date of retesting of the active substance may indicate the moment when the material must be reevaluated before further use in accordance with the appropriate quality system.
This is not a general instruction allowing the consumer to extend the expiration date of a finished medicinal product.
Shelf life or expiration date refers to the preservation of compliance with specified specifications under specified conditions.
Both concepts are based on data and depend on the category of material.
Changing the storage location does not start these periods anew.
Placing an older preparation at a lower temperature cannot reverse its previous history or automatically create a new, validated period of stability.
Temperature deviations require evaluation in the appropriate context
Temperature deviation occurs when the material is outside the specified range of storage conditions.
The significance of such an event depends on more than just the fact that a deviation occurred.
The duration of the time is important.
The significance of the difference in temperature is great.
The earlier history of the storage of the preparation is important.
Above all, however, appropriate stability data are needed to assess the significance of a given event.
The general table found on the internet cannot determine the suitability of an unidentified preparation after an unknown temperature deviation.
In the case of a medicinal product that has been authorized for marketing, the basis for the assessment should be appropriate product information and, if necessary, data from the manufacturer, pharmacist, or other appropriate specialist.
In the case of laboratory materials, the applicable quality procedures, the supplier's documentation, and the requirements of the specific experiment are of importance.
The stability requirement should always remain within the limits of what actually results from the available evidence.
Proper storage can help preserve the properties of previously defined materials.
However, it cannot confirm its identity, sterility, purity, or suitability for human use unless these properties have previously been properly demonstrated.
Frequently asked questions
1. Do all peptides require storage in a freezer?
No. The term „peptide” describes a broad category of molecules, not a single standard formulation. Storage conditions depend on the specific peptide, its physical state, formulation, packaging, and intended use. For some preparations, there may be data justifying storage in a frozen state, for others in refrigerated conditions, and for still others under different validated conditions. Freezing itself can cause physical changes, so it should not be automatically considered the safest option. Storage conditions should be based on data specific to the particular preparation, and not solely on the fact that it contains a peptide.
2. Does the storage temperature itself determine the shelf life?
No. The temperature value alone, without information about time, formulation, packaging system, and evaluated quality parameters, does not allow determining the shelf life. Shelf life refers to whether certain properties remain at an acceptable level for a given period under specific conditions. Two preparations stored at the same temperature may behave differently due to differences in sequence, formulation, moisture content, packaging, or other properties. The refrigerator temperature is therefore a condition of storage, not an independent proof of durability.
3. Are lyophilized peptides completely water-free?
Not necessarily. Freezing-drying removes a significant amount of water, but residual moisture may remain in the resulting material. This can affect the mobility of molecules, physical properties, and degradation pathways. Based on the appearance of the dry powder or freeze-dried product, the residual moisture content cannot be determined. Dry appearance, low water content, and confirmed stability are three different concepts.
4. Can the peptide degrade into a powder form?
Yes. Drying can slow down or change some degradation pathways, but it does not stop all chemical reactions. In studies of dried peptide systems, among other things, deamidation and the formation of covalent products were observed under certain experimental conditions. This does not mean that every powder peptide will behave in the same way. However, it shows why the assumption that „powder means no chemical changes” is incorrect. Stability must be determined for a specific preparation.
5. Are powder peptides always more stable than peptide solutions?
There is no universal comparison. Removing a significant amount of water can limit some reactions occurring in the solution, but dry materials have their own physical and chemical environment. Their behavior can be influenced by residual moisture, auxiliary substances, and solid-state properties. Solutions, in turn, introduce variables such as pH, solvent composition, concentration, aggregation, or surface adsorption. Therefore, the scientifically relevant question is not whether a powder or solution is always better, but which specific formulation maintains the required properties under validated conditions.
6. Does the clear solution mean that the peptide has remained intact?
No. Transparency allows one to conclude primarily that no clear precipitation or visible particles are observed. However, many chemical changes remain invisible. A peptide can undergo oxidation, deamidation, or other molecular modifications while the solution still appears completely transparent. Visible particles, on the other hand, can indicate physical instability but do not explain its chemical mechanism. The appearance may therefore be one element of observation, but it does not replace the analytical assessment of chemical integrity.
7. Is the lowest possible temperature always the best?
No. Lower temperatures can slow down some degradation reactions, but freezing causes additional physical changes that do not occur during normal refrigeration storage. The formation of ice, the increase in the concentration of substances dissolved in un-frozen areas, and the formation of new interfacial surfaces can affect some preparations. The balance between the slowing down of chemical reactions and the stress associated with freezing depends on the specific material. Therefore, the lowest available temperature should not be automatically considered to be scientifically optimal.
8. Does one cycle of freezing and thawing destroy every peptide?
No. There are no scientific grounds for the universal claim that one cycle of freezing and thawing destroys every peptide. Individual molecules, formulations, and sample matrices can react differently. Research on biological samples shows that even analytes present in the same sample can exhibit varying sensitivity to repeated cycles. However, the results of such studies cannot be automatically transferred to purified peptide preparations. The effect of freezing and thawing should be evaluated for a specific material and a specific tested property.
9. Is there a standard safe number of freezing and thawing cycles?
No. One universal number cannot be assigned to all peptide preparations. One study may measure chemical concentration, another biological activity, a third aggregation, and yet another analytical recovery. A preparation may be acceptable according to one criterion while showing variation according to another. Therefore, the validated limit for freezing and thawing cycles applies to a specific material, its formulation, and the specific method of defining acceptability.
10. Can a peptide „disappear” from a solution without undergoing chemical degradation?
Yes. A peptide can bind to the surface of the container or another component of the analytical system. This process, called adsorption, can reduce the amount of peptide remaining in the main volume of the liquid, thereby reducing the measured recovery without the need for chemical destruction of the molecule. Deletion and aggregation can also reduce the amount of material detected in the solution. Therefore, a lower analytical signal should not be automatically interpreted as evidence of chemical degradation.
11. Is glass always better than plastic for storing peptides?
No. Glass and plastic are broad categories of materials, not a universal ranking of quality. Surface properties, manufacturing method, container geometry, peptide concentration, and the characteristics of the molecule itself can all influence the effects. Specialty containers with limited binding can be useful in certain applications, but their advantages should not be assumed without appropriate data. The usefulness of a specific container is therefore a matter of product and application-specific considerations.
12. Do low-binding tubes guarantee complete recovery of the peptide?
No. Materials with limited binding ability can reduce certain interactions with the surface, but they do not guarantee the recovery of every molecule. Adsorption can also occur in other parts of the process, including the equipment used to prepare samples or in the analytical system. Aggregation, precipitation, and chemical degradation can further reduce recovery through completely different mechanisms. Therefore, the container’s favorable properties only address one component of the broader problem of stability and analysis.
13. Does the miniload designed for peptides guarantee proper storage?
No. A separate refrigerator can be a useful device, but its name does not specify the conditions required by a specific preparation. The equipment must actually maintain an appropriate environment, and for the preparation itself there must be data confirming the ability to store it under such conditions. A mini-refrigerator does not independently confirm the uniformity of temperature, does not eliminate the risk of accidental freezing, and does not establish a shelf life. The device’s properties and the stability of the preparation are related but separate issues.
14. Does the expiration date of an unopened product apply even after it is opened?
Not automatically. Repeated use of the contents can increase contact with air, moisture, surfaces, or temperature changes. Dissolving or diluting can further alter the physical state and chemical environment of the product. Therefore, the shelf life established for an unopened product should not be automatically applied to the product after opening, dilution, or dissolution unless the corresponding data confirms this.
15. Does the analysis certificate confirm the future stability of the peptide?
No. The analysis certificate usually presents specific results of the tests on the identified material at a specific moment or at a specific stage. It can contain valuable information regarding, for example, identity, content, or purity according to the tests performed. However, stability answers another question: how do the relevant properties change over time under specific conditions? A correct result obtained today does not in itself prove that the same preparation will remain unchanged over a specified period in the future.
16. Can a blood sample test determine the storage conditions of the peptide in the vial?
No. Blood, serum or plasma and purified peptide preparation are different chemical and physical environments. Biological samples contain proteins, salts, metabolites, lipids and many other substances that can affect the analyte’s behavior. A study showing that a specific peptide or hormone remains detectable in the plasma after repeated freezing does not automatically confirm structural integrity or the appropriate storage conditions for the purified preparation. The sample matrix and the analytical parameter being evaluated are an integral part of such a conclusion.
17. Does stability mean that the peptide is suitable for human use?
No. Stability determines whether the defined properties remain acceptable under specific conditions. It does not independently verify identity, sterility, quality of production, regulatory approval, clinical efficacy, or suitability for human use. Chemical stability and microbiological quality are also separate characteristics. The investigational material may therefore remain chemically stable, but this does not mean that it becomes a ready-to-use or approved medicinal product.
Summary
The storage of peptides does not require a single temperature, a single type of container, or a single universal shelf life period.
The stability of a peptide preparation depends on the specific molecule, formulation, physical state, concentration, moisture content, packaging, exposure to environmental factors, history of handling the material, and quality parameters subject to evaluation.
Temperature is important because it can affect the speed of the reaction, but a lower temperature does not always mean better conditions. Freezing changes the physical environment of the solution and can cause other types of stress than conventional cooling. For this reason, storing in a frozen state should be based on data specific to the particular preparation, rather than assuming that freezing always provides the best protection.
Moisture is equally important. Freeze-drying and other drying methods can reduce the water content and improve stability in suitable systems, but the dry material does not have to be completely devoid of water or chemically inactive. Residual moisture can affect both chemical reactions and the material's stability in its solid state.
Solutions introduce additional variables. The decrease in the measured concentration of the peptide can be due to chemical degradation, but it can also be the result of aggregation, precipitation, or adsorption on surfaces. These mechanisms should not be treated as equivalent just because each can lead to a reduction in the analytical signal.
The same level of caution requires the selection of the container. Glass, plastic, and specialized materials with limited binding properties cannot be grouped into a single universal way without taking into account the specific peptide and application. A container suitable for one analytical preparation does not necessarily provide the same benefits for another material.
The influence of freezing and thawing cannot be reduced to a single allowable number of cycles. Different materials and analytical parameters may react differently, and the results obtained for proteins or biological samples cannot be automatically used to determine the storage limits for purified short peptides.
The most important principle is therefore that the information regarding storage should be specific to the particular preparation and based on relevant data.
A reliable claim indicates what material was tested, in what formulation and packaging, under what conditions, for how long, and according to which analytical criteria.
Terms such as „stored in the refrigerator,” „frozen,” „lyophilized,” „low-binding,” „stable,” or „peptide refrigerator” describe only individual elements of the subject matter. None of these terms alone determines the shelf life.
Stability should not be equated with broader conclusions regarding quality or clinical use. Demonstrating that a peptide remains chemically or physically stable does not in itself confirm its identity, sterility, market approval, clinical efficacy, or suitability for human use.
Stability studies answer a narrower, but important question: do the specific properties of a particular preparation remain at an acceptable level for a specified period under defined conditions?.
Disclaimer
This article is for educational, scientific and informational purposes only. Its purpose is to present general principles regarding the stability of peptides, storage studies, the influence of temperature and humidity, freezing and thawing cycles, interactions with the container surfaces, and stability documentation. This article does not constitute medical advice, recommendations regarding product selection, preparation or reconstitution instructions, dosage instructions, storage instructions for a specific medicinal product or research material, or recommendations regarding the use of any peptide.
Storage conditions depend on the specific material, formulation, and product. Information derived from model studies of peptides, proteins, biological samples, analytical patterns, or specific pharmaceutical formulations should not be automatically used as a basis for determining storage conditions for another peptide or formulation. Temperatures, storage times, and freeze-drying and thawing cycles specified for one material cannot be automatically transferred to another.
For medicinal products that are placed on the market, the storage and handling conditions specified in the relevant approved product information and the instructions of the manufacturer or the competent health care professional must be followed. For laboratory materials, investigators should rely on validated stability data, applicable laboratory procedures, the supplier's documentation, and the quality requirements of the institution or the relevant regulations applicable to the specific material and experiment.
Chemical or physical stability alone does not confirm the identity, purity, sterility, endotoxin levels, clinical safety, efficacy, regulatory approval, or suitability for human use. Each of these elements constitutes a separate qualitative or evidentiary issue and requires appropriate evaluation.
References
- Dehart, M. P., & Anderson, B. D. (2012). Kinetics and mechanisms of deamidation and covalent amide-linked adduct formation in amorphous lyophiles of a model asparagine-containing peptide. Pharmaceutical Research, 29(10), 2722–2737. https://doi.org/10.1007/s11095-011-0591-6
- Judák, P., Van Eenoo, P., & Deventer, K. (2017). Adsorption effects of the doping-relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5. Analytical Biochemistry, 537, 69–71. https://doi.org/10.1016/j.ab.2017.09.003
- Hillebrand, J. J., Heijboer, A. C., & Endert, E. (2017). Effects of repeated freeze-thaw cycles on endocrine parameters in plasma and serum. Annals of Clinical Biochemistry, 54(2), 289–292. https://doi.org/10.1177/0004563216657361
- Chawathe, A., & Sharma, N. (2026). Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide. Journal of Pharmaceutical and Biomedical Analysis, 272, Article 117362. https://doi.org/10.1016/j.jpba.2026.117362
- Dubost, D. C., Kaufman, M. J., Zimmerman, J. A., Bogusky, M. J., Coddington, A. B., & Pitzenberger, S. M. (1996). Characterization of a solid state reaction product from a lyophilized formulation of a cyclic heptapeptide. A novel example of an excipient-induced oxidation. Pharmaceutical Research, 13(12), 1811–1814. https://doi.org/10.1023/a%3A1016024923002
- Doerr, F. J. S., Burns, L. J., Lee, B., Hinds, J., Davis-Harrison, R. L., Frank, S. A., & Florence, A. J. (2020). Peptide isolation via spray drying: Particle formation, process design and implementation for the production of spray dried glucagon. Pharmaceutical Research, 37(12), Article 255. https://doi.org/10.1007/s11095-020-02942-5
- International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf
- DeHart, M. P., & Anderson, B. D. (2012). Effects of water and polymer content on covalent amide-linked adduct formation in peptide-containing amorphous lyophiles. Journal of Pharmaceutical Sciences, 101(9), 3142–3156. https://doi.org/10.1002/jps.23092
- Zhang, A., Qi, W., Singh, S. K., & Fernandez, E. J. (2011). A new approach to explore the impact of freeze-thaw cycling on protein structure: Hydrogen/deuterium exchange mass spectrometry (HX-MS). Pharmaceutical Research, 28(5), 1179–1193. https://doi.org/10.1007/s11095-011-0383-z
- Zhang, Y., Yang, J., Ma, Y., Cao, L., & Huang, Q. (2022). [Evaluation of nonspecific adsorption and general minimization strategy in peptide analysis based on ultra-performance liquid chromatography-mass spectrometry]. Se Pu (Chinese Journal of Chromatography), 40(7), 616–624. https://doi.org/10.3724/SP.J.1123.2021.12012
- U.S. Food and Drug Administration. (2016, September). Q7 guidance on good manufacturing practice for active pharmaceutical ingredients: Guidance for industry. https://www.fda.gov/media/71518/download
- European Agency for the Evaluation of Medicinal Products. (2001). Note for guidance on in-use stability testing of human medicinal products. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-human-medicinal-products_en.pdf